Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2426456
Max Phase: Preclinical
Molecular Formula: C34H48N2O8S
Molecular Weight: 644.83
Molecule Type: Small molecule
Associated Items:
ID: ALA2426456
Max Phase: Preclinical
Molecular Formula: C34H48N2O8S
Molecular Weight: 644.83
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(S(=O)(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@@H]2CC(C)(C)C[C@@H]3O[C@H]4OCC[C@H]4[C@@H]32)cc1
Standard InChI: InChI=1S/C34H48N2O8S/c1-22(2)20-36(45(39,40)25-13-11-24(41-5)12-14-25)21-28(37)27(17-23-9-7-6-8-10-23)35-33(38)44-30-19-34(3,4)18-29-31(30)26-15-16-42-32(26)43-29/h6-14,22,26-32,37H,15-21H2,1-5H3,(H,35,38)/t26-,27-,28+,29-,30+,31-,32+/m0/s1
Standard InChI Key: DSIZTJKHNCNJNW-KTKZCLBLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 644.83 | Molecular Weight (Monoisotopic): 644.3131 | AlogP: 4.61 | #Rotatable Bonds: 12 |
Polar Surface Area: 123.63 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 10 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 13.62 | CX Basic pKa: | CX LogP: 4.83 | CX LogD: 4.83 |
Aromatic Rings: 2 | Heavy Atoms: 45 | QED Weighted: 0.34 | Np Likeness Score: 0.29 |
1. Ghosh AK, Parham GL, Martyr CD, Nyalapatla PR, Osswald HL, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.. (2013) Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies., 56 (17): [PMID:23947685] [10.1021/jm400768f] |
Source(1):